Implantable system for treprostinil: a real-world patient experience study

Implantable system for treprostinil: a real-world patient experience study

Parenteral prostanoids are effective for improving outcomes in patients with pulmonary arterial hypertension. However, subcutaneous or intravenous delivery via an external pump places a significant burden on patients. Consequently, the Implantable System for Remodulin© (treprostinil) was developed a...

Full description

Bibliographic Details
Main Authors:	Shelley Shapiro, Robert C. Bourge, Patti Pozella, David F. Harris, Erick H. Borg, Andrew C. Nelsen
Format:	Article
Language:	English
Published:	Wiley 2020-04-01
Series:	Pulmonary Circulation
Online Access:	https://doi.org/10.1177/2045894020907881

Similar Items

Dosing characteristics of oral treprostinil in real-world clinical practice
by: Vijay P. Balasubramanian, et al.
Published: (2018-07-01)

Real‐world dosing characteristics and utilization of parenteral treprostinil in the outpatient setting
by: Vijay P. Balasubramanian, et al.
Published: (2022-01-01)

Implantable system for treprostinil and lung transplantation: case series from delivery for pulmonary arterial hypertension study
by: Jeremy P. Feldman, et al.
Published: (2021-03-01)

Characterisation of cough evoked by inhaled treprostinil and treprostinil palmitil
by: Richard W. Chapman, et al.
Published: (2021-02-01)

Real-world evidence of subcutaneous treprostinil use in pulmonary arterial hypertension in Argentina
by: Adrián Lescano, et al.
Published: (2022-10-01)

Treprostinil for pulmonary hypertension
by: Nika Skoro-Sajer, et al.
Published: (2008-06-01)

Experiences with treprostinil in the treatment of pulmonary arterial hypertension
by: Amanda R. Stream, et al.
Published: (2012-10-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
by: Shelsey W. Johnson, et al.
Published: (2022-07-01)

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension
by: Susanna Desole, et al.
Published: (2018-12-01)

Impact of inhaled treprostinil on risk stratification with noninvasive parameters: a post hoc analysis of the TRIUMPH and BEAT studies
by: Adriano R. Tonelli, et al.
Published: (2020-12-01)

Implementing the EXPEDITE parenteral induction protocol: Rapid parenteral treprostinil titration and transition to oral treprostinil
by: John F. Kingrey, et al.
Published: (2023-07-01)

Oral treprostinil use in children: a multicenter, observational experience
by: Usama Kanaan, et al.
Published: (2019-07-01)

An implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinil
by: Marcin Kurzyna, et al.
Published: (2017-12-01)

Novel dose–response analyses of treprostinil in pulmonary arterial hypertension and its effects on six-minute walk distance and hospitalizations
by: Gautam Ramani, et al.
Published: (2020-06-01)

Periprocedural safety and outcome after pump implantation for intravenous treprostinil administration in patients with pulmonary arterial hypertension
by: Jan C. Kamp, et al.
Published: (2021-05-01)

Long-term study of oral treprostinil to treat pulmonary arterial hypertension: dosing, tolerability, and pharmacokinetics
by: R. James White, et al.
Published: (2020-12-01)

Inhaled treprostinil: a therapeutic review
by: Channick RN, et al.
Published: (2012-01-01)

Extended-release oral treprostinil in the management of pulmonary arterial hypertension: clinical evidence and experience
by: James C. Coons, et al.
Published: (2018-03-01)

Long-term experience with implantable infusion pumps for intravenous treprostinil in pulmonary arterial hypertension—procedural safety and system-related complications
by: Regina Steringer-Mascherbauer, et al.
Published: (2020-11-01)

Successful management of an inadvertent excessive treprostinil overdose
by: Hohenforst-Schmidt W, et al.
Published: (2013-03-01)

Flow rate variance of a fully implantable pump for the delivery of intravenous treprostinil in pulmonary arterial hypertension
by: Manuel J. Richter, et al.
Published: (2020-03-01)

Evaluation and Selection of the Inhaler Device for Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2022-04-01)

Effect of Inhalation Profile on Delivery of Treprostinil Palmitil Inhalation Powder
by: Helena Gauani, et al.
Published: (2023-03-01)

Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension
by: D. Dunbar Ivy, et al.
Published: (2019-07-01)

Intravenous Treprostinil in Severe Inoperable Chronic Thromboembolic Pulmonary Hypertension Using Implantable Pumps—Single-Center Experience over More Than a Decade
by: Regina Steringer-Mascherbauer, et al.
Published: (2023-07-01)

Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation
by: Alex J. Chang, MD, et al.
Published: (2024-03-01)

Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch
by: Ibrahim Alissa, et al.
Published: (2023-04-01)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
by: Carlo Arevalo, et al.
Published: (2022-01-01)

Venoarterial extracorporeal membrane oxygenation for vasoplegic shock after treprostinil refill of an implanted intravenous pump: a case report
by: Lucía Valencia, et al.
Published: (2024-01-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
by: Nicholas S. Hill, et al.
Published: (2022-07-01)

Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil
by: Robert Roscigno, et al.
Published: (2020-11-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
by: Garance Kopp, et al.
Published: (2020-10-01)

Treprostinil Reconstitutes Mitochondrial Organisation and Structure in Idiopathic Pulmonary Fibrosis Cells
by: Lei Fang, et al.
Published: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
by: Julia McSweeney, et al.
Published: (2023-04-01)

Development and Characterization of Treprostinil Palmitil Inhalation Aerosol for the Investigational Treatment of Pulmonary Arterial Hypertension
by: Adam J. Plaunt, et al.
Published: (2021-01-01)

Impact of four times daily dosing of oral treprostinil on tolerability and daily dose achieved in pulmonary hypertension
by: James C. Coons, et al.
Published: (2017-11-01)

Pulmonary Hypertension-Associated Right Ventricular Cardiomyocyte Remodelling Reduces Treprostinil Function
by: Aleksandra Judina, et al.
Published: (2023-12-01)

Short term effect of intravenous treprostinil in term and preterm infants with pulmonary hypertension
by: Yoo-Jin Kim, et al.
Published: (2024-01-01)

Efficacy, safety, and pharmacokinetics of inhaled treprostinil in Japanese patients with pulmonary arterial hypertension
by: Masataka Kuwana, et al.
Published: (2023-01-01)

Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension
by: Asuka Furukawa, et al.
Published: (2017-10-01)